36,446 results match your criteria sle


Vitamin D in systemic lupus erythematosus with and without lupus nephritis.

Rev Med Inst Mex Seguro Soc 2020 ;58(4):394-399

Laboratorios Clínicos de Puebla, Sucursal Anzures, Dirección de Proyectos Especiales. Puebla, Puebla, México.

IntroducciÓn: Las concentraciones séricas subóptimas de vitamina D se presentan en múltiples enfermedades crónicas, como las enfermedades autoinmunitarias. Los objetivos del estudio fueron: 1) comparar las concentraciones séricas de 25-hidroxivitamina D (25OHD3) en pacientes con lupus eritematoso sistémico (LES) con y sin nefritis lúpica (NL), y 2) evaluar la asociación de las concentraciones séricas de 25OHD3 con la actividad de la enfermedad.

Material Y MÉtodos: Estudio comparativo, transversal, que incluyó 48 mujeres con LES, con y sin NL. Read More

View Article and Full-Text PDF
January 2020

Study of antiphospholipid antibodies by enzyme immunoassay and chemiluminescent methods in patients with antiphospholipid syndrome and systemic lupus erythematosus (preliminary data).

Klin Lab Diagn 2021 Sep;66(9):546-551

V.A. Nasonova Research Institute of Rheumatology, Laboratory of Vascular Rheumatology.

Antiphospholipid antibodies (aPL) are a family of different autoantibodies that lead to recurrent vascular thrombosis of any localization and caliber, and/or obstetric pathology - fetal loss. Serological markers of antiphospholipid syndrome (APS) include only three types of aPL - lupus anticoagulant (VA), antibodies to cardiolipin (aCL) classes IgG and IgM, antibodies to β2-glycoprotein1 (aβ2GP1) classes IgG and IgM. Medium and high levels of aCL and aß2HP1 (IgG and / or IgM) were selected as serological markers of APS in the 2006 classification criteria. Read More

View Article and Full-Text PDF
September 2021

A potential diagnostic serum immunological marker panel to differentiate between primary and secondary knee osteoarthritis.

PLoS One 2021 20;16(9):e0257507. Epub 2021 Sep 20.

Faculty of Science, Department of Zoology & Environment Sciences, University of Colombo, Colombo, Sri Lanka.

Inflammation contributes to knee osteoarthritis (KOA) where many immunological mediators participate in its initiation and progression. Most clinicians manage primary (pKOA) and secondary osteoarthritis (sKOA) alike. Whether immunological profiles of pKOA and sKOA differ remains obscure. Read More

View Article and Full-Text PDF
September 2021

Evaluation of Disease Activity of Systemic Lupus Erythematosus by D-dimer Combined with Red Blood Cell Distribution Width.

Clin Lab 2021 Sep;67(9)

Background: To investigate the value of D-dimer combined with red blood cell distribution width (RDW) in evaluating the disease activity of systemic lupus erythematosus (SLE).

Methods: A total of 105 SLE patients confirmed in our hospital from July 2018 to September 2020 were collected as the SLE group, and 60 healthy persons matched in age and gender during the same period were collected as the control group. According to the SLEDAI score, SLE patients were divided into SLE active group and SLE inactive group, and RDW and D-Dimer levels were detected. Read More

View Article and Full-Text PDF
September 2021

The Therapeutic Strategies for SLE by Targeting Anti-dsDNA Antibodies.

Clin Rev Allergy Immunol 2021 Sep 20. Epub 2021 Sep 20.

Department of Dermatology, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.

Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by diverse serological autoantibodies. Anti-dsDNA antibodies are involved in multiple organ damage, especially the kidney, skin, and central nervous system. Anti-dsDNA antibodies play a pivotal role in SLE, and researchers have developed therapeutic strategies targeting these antibodies. Read More

View Article and Full-Text PDF
September 2021

Phos-tag Immunoblot Analysis for Detecting IRF5 Phosphorylation.

Bio Protoc 2017 May 20;7(10):e2295. Epub 2017 May 20.

Department of Immunology, Yokohama City University Graduate School of Medicine, Yokohama, Japan.

While the activation of the transcription factor interferon regulatory factor 5 (IRF5) is critical for the induction of innate immune responses, it also contributes to the pathogenesis of the autoimmune disease systemic lupus erythematosus (SLE). IRF5 phosphorylation is a hallmark of its activation in the Toll-like receptor (TLR) pathway, where active IRF5 induces type I interferon and proinflammatory cytokine genes. By using the phosphate-binding molecule Phos-tag, without either radioisotopes or phospho-specific antibodies, the protocol described here enables detection of the phosphorylation of both human and murine IRF5, as well as that of other proteins. Read More

View Article and Full-Text PDF

The Th17/IL-17 Axis and Kidney Diseases, With Focus on Lupus Nephritis.

Front Med (Lausanne) 2021 3;8:654912. Epub 2021 Sep 3.

Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil.

Systemic lupus erythematosus (SLE) is a disease characterized by dysregulation and hyperreactivity of the immune response at various levels, including hyperactivation of effector cell subtypes, autoantibodies production, immune complex formation, and deposition in tissues. The consequences of hyperreactivity to the self are systemic and local inflammation and tissue damage in multiple organs. Lupus nephritis (LN) is one of the most worrying manifestations of SLE, and most patients have this involvement at some point in the course of the disease. Read More

View Article and Full-Text PDF
September 2021

Secukinumab on Refractory Lupus Nephritis.

Cureus 2021 Aug 15;13(8):e17198. Epub 2021 Aug 15.

Internal Medicine, Centro Hospitalar do Porto, Porto, PRT.

Lupus nephritis (LN) is the most frequent severe organ manifestation of systemic lupus erythematosus (SLE). About 30% of patients are refractory to treatment. The authors report a case of treatment of LN with interleukin-17-targeted therapy, demonstrating its possible benefit, after reports of T helper 17 cell involvement in SLE pathogenesis. Read More

View Article and Full-Text PDF

Systemic lupus erythematosus and critical illness polyneuropathy.

Reumatologia 2021 26;59(4):265-269. Epub 2021 Aug 26.

Rehabilitation Clinic, National Institute of Geriatrics, Rheumatology and Rehabilitation, Warsaw, Poland.

Systemic lupus erythematosus (SLE) is a chronic disease of connective tissue with multi-organ involvement. Manifestation in the nervous system is one of the most difficult symptoms to assess and interpret. The aim of the study is to indicate diagnostic problems in patients with SLE in whom neurological symptoms are present at the time of diagnosis of SLE but also with complications that occurred after diagnosis. Read More

View Article and Full-Text PDF

Follow-up and management of serologically active clinically quiescent cases in pediatric systemic lupus erythematosus.

Reumatologia 2021 13;59(4):244-251. Epub 2021 Aug 13.

Department of Pediatric Rheumatology, University at Buffalo, United States.

Objectives: Our aim is to identify the presence of serologically active clinically quiescent (SACQ) episodes in pediatric systemic lupus erythematosus (SLE) patients. We aim to identify serologic biomarkers associated with SACQ episodes and discuss risks and benefits of escalating treatments.

Material And Methods: We evaluated 25 pediatric SLE patients, 13 of whom experienced SACQ episodes. Read More

View Article and Full-Text PDF

Challenges of Egyptian patients with systemic lupus erythematosus during the COVID-19 pandemic.

Reumatologia 2021 20;59(4):237-243. Epub 2021 Aug 20.

Mansoura Nephrology and Dialysis Unit, Department of Internal Medicine, Mansoura University, Faculty of Medicine, Egypt.

Objectives: The coronavirus disease 2019 (COVID-19) pandemic in Egypt is part of the worldwide COVID-19 pandemic that has contributed to substantial deterioration of healthcare systems. The aim of this study was to assess the challenges faced by Egyptian systemic lupus erythematosus (SLE) patients during the COVID-19 pandemic.

Material And Methods: This questionnaire-based study was carried out on 200 patients with SLE from Egypt. Read More

View Article and Full-Text PDF

Vitamin D supply in patients with rheumatic diseases in Poland - a pilot study.

Reumatologia 2021 11;59(3):146-152. Epub 2021 Jul 11.

Department of Rheumatology, Rehabilitation and Internal Medicine, Poznan University of Medical Sciences, Poland.

Objectives: In rheumatic diseases, vitamin D supply is recommended as part of the prophylaxis and treatment of osteoporosis, especially in patients undergoing glucocorticoid therapy, but also due to its immunoregulatory and anti-inflammatory properties. We aimed to evaluate serum 25-hydroxyvitamin D [25(OH)D] levels in Polish patients with systemic sclerosis (SSc), systemic lupus erythematosus (SLE) and granulomatosis with polyangiitis (GPA), in relation to various clinical parameters, and to assess the initial range of doses for the purpose of further research.

Material And Methods: 112 patients (39 with SLE, 44 with SSc and 29 with GPA), referred to the Department of Rheumatology and Internal Medicine in Poznan, Poland, were enrolled in this retrospective study. Read More

View Article and Full-Text PDF

Is lupus nephritis a prognosis factor for pregnancy? Maternal and foetal outcomes.

Reumatol Clin (Engl Ed) 2021 Sep 17. Epub 2021 Sep 17.

Hospital Materno Neonatal de la Provincia de Córdoba, Córdoba, Argentina; Hospital Córdoba, Córdoba, Argentina; Cátedra de Semiología, Hospital Córdoba, Facultad de Ciencias Médicas, Universidad Nacional de Córdoba, Córdoba, Argentina. Electronic address:

Background: Pregnancy in women with systemic lupus erythematosus (SLE) and nephritis (LN) is at risk of foetal and maternal complications.

Objective: To evaluate the effect of LN on pregnancy with respect to foetal and maternal outcome.

Methods: We retrospectively studied all pregnant SLE patients with and without diagnosis of LN, who attended the Materno Neonatal Hospital in Cordoba city, Argentina, from January 2015 to April 2017. Read More

View Article and Full-Text PDF
September 2021

Association of TNFSF4 polymorphisms with systemic lupus erythematosus: a meta-analysis.

Adv Rheumatol 2021 Sep 19;61(1):59. Epub 2021 Sep 19.

Key Laboratory of Drug Targeting and Drug Delivery System of the Education Ministry, Sichuan Engineering Laboratory for Plant-Sourced Drug and Sichuan Research Center for Drug Precision Industrial Technology, West China School of Pharmacy, Sichuan University, Chengdu, 610064, China.

Objective: To more precisely estimate the association between the tumor necrosis factor ligand superfamily member 4 (TNFSF4) gene polymorphisms and systemic lupus erythematosus (SLE) susceptibility, we performed a meta-analysis on the association of the following single nucleotide polymorphisms (SNPs) of TNFSF4 with SLE: rs1234315, rs844648, rs2205960, rs704840, rs844644, rs10489265.

Methods: A literature-based search was conducted using PubMed, MEDLINE, Embase, Web of Science databases, and Cochrane Library databases to identify all relevant studies. And the association of TNFSF4 gene polymorphisms and SLE susceptibility was evaluated by pooled odds ratio (OR) with 95% confidence interval (CI). Read More

View Article and Full-Text PDF
September 2021

Serum BDNF and cognitive dysfunction in SLE: findings from a cohort of 111 patients.

Clin Rheumatol 2021 Sep 19. Epub 2021 Sep 19.

Division of General Neurology and Ataxias, Department of Neurology and Neurosurgery, Universidade Federal de São Paulo, São Paulo, Brazil.

Objective: The association between brain-derived neurotrophic factor (BDNF) and neuropsychiatric systemic lupus erythematosus (NPSLE) is controversial in the literature. Cognitive dysfunction (CD) is a common, underdiagnosed NPSLE manifestation, but its pathophysiology is unknown. Thus, we investigate serum BDNF as a potential biomarker of CD in a cohort of SLE patients. Read More

View Article and Full-Text PDF
September 2021

Systemic lupus erythematosus and autoimmune features in chronic hospitalized patients with schizophrenia.

Schizophr Res 2021 Sep 15;237:166-173. Epub 2021 Sep 15.

Department of Medical Research, Taichung Veterans General Hospital, Taichung, Taiwan; Department of Public Health, College of Medicine, Fu Jen Catholic University, New Taipei City, Taiwan; Institute of Genomics and Bioinformatics, National Chung Hsing University, Taichung, Taiwan. Electronic address:

Objectives: Recent studies highlighted the link of schizophrenia risk with genetic variations in complement, which share the same pathogenesis with systemic lupus erythematosus (SLE). However, the coexistence of SLE and schizophrenia were rarely reported. We aimed to explore the autoantibody profiles, complement levels and prevalence of SLE in chronic schizophrenia patients. Read More

View Article and Full-Text PDF
September 2021

The altered functional modular organization in systemic lupus erythematosus: an independent component analysis study.

Brain Imaging Behav 2021 Sep 18. Epub 2021 Sep 18.

Department of Radiology, Subei People's Hospital of Jiangsu Province, Central South University, No.98 Nantong West Road, Yangzhou, 225001, Jiangsu, China.

The aim of this study was to investigate the abnormities in functional connectivity (FC) within each modular network and between modular networks in patients with systemic lupus erythematosus (SLE). Twelve meaningful modular networks were identified via independent component analysis from 41 patients and 40 volunteers. Parametric tests were used to compare the intra- and intermodular FC between the groups. Read More

View Article and Full-Text PDF
September 2021

Maternal disease activity and serological activity as predictors of adverse pregnancy outcomes in women with systemic lupus erythematosus: a retrospective chart review.

Arch Gynecol Obstet 2021 Sep 17. Epub 2021 Sep 17.

Department of Obstetrics and Gynecology, Fukushima Medical University School of Medicine, 1 Hikarigaoka, Fukushima, 960-1295, Japan.

Purpose: To evaluate the association between disease activity, serological activity, and adverse pregnancy outcomes (APOs) in women with systemic lupus erythematosus (SLE) and determine the cut-off values of complements to predict APOs in live birth cases.

Methods: This retrospective chart review included pregnant women with SLE who had singleton live births after 22 weeks between 2006 and 2020. First trimester maternal disease activity was assessed for SLE onset during pregnancy, antiphospholipid syndrome, SLE pregnancy disease activity index (SLEPDAI), disease flare-ups, lupus nephritis, pancytopenia, and daily prednisolone dosage. Read More

View Article and Full-Text PDF
September 2021

IgG anti-Pentraxin 3 antibodies are a novel biomarker of ANCA-associated vasculitis and better identify patients with eosinophilic granulomatosis with polyangiitis.

J Autoimmun 2021 Sep 14;124:102725. Epub 2021 Sep 14.

Division of Rheumatology, Department of Medicine DIMED, University of Padova, Italy. Electronic address:

Objective: To investigate prevalence of anti-Pentraxin 3 (PTX3) antibodies in sera of anti-neutrophil cytoplasmic antibodies (ANCA)-associated vasculitis (AAV) patients.

Methods: Anti-PTX3 and PTX3 levels were analysed by enzyme-linked immunosorbent assays in sera from unselected patients with AAV and compared with patients with systemic lupus erythematosus (SLE, n = 130), other connective tissue diseases (CTDs, n = 97) and matched healthy controls (n = 97). Optical density (OD) cut-off for positive anti-PTX3 antibodies was determined by ROC curve analysis and set as 0. Read More

View Article and Full-Text PDF
September 2021

Joint involvement in Noonan syndrome.A retrospective paediatric descriptive study.

Joint Bone Spine 2021 Sep 14:105270. Epub 2021 Sep 14.

Rheumatology Department, CHU Cavale Blanche, Center of Autoimmune Rare Diseases (CERAINO), Brest, France; UMR1227, INSERM, Université de Bretagne Occidentale, Brest, France. Electronic address:

Objectives: Noonan syndrome is a rare genetic disorder characterized mainly by congenital heart disease, occasional intellectual disability, and varied orthopaedic, rheumatological and haematologic anomalies. Despite potentially serious functional consequences, joint involvement has been rarely studied in the literature. Our objective was to perform a retrospective study evaluating the prevalence and characteristics of joint involvement in Noonan syndrome. Read More

View Article and Full-Text PDF
September 2021

CTLA-4 polymorphisms in Thai patients with rheumatoid arthritis, systemic lupus erythematosus, and systemic sclerosis.

Int J Rheum Dis 2021 Sep 17. Epub 2021 Sep 17.

School of Pharmacological Sciences, University of Shizuoka, Shizuoka, Japan.

Aims: Studies on polymorphisms of the cytotoxic T lymphocytes associated antigen-4 (CTLA-4) genes in rheumatic disease patients are limited in Southeast Asia. This pilot study aimed to determine CTLA-4 polymorphisms in Thai patients with rheumatoid arthritis (RA), systemic lupus erythematosus (SLE) and systemic sclerosis (SSc), and correlate them with serology.

Method: One-hundred RA, 70 SLE and 50 SSc patients, and 99 healthy controls (HCs) were included in this study. Read More

View Article and Full-Text PDF
September 2021

Autoimmune-mediated renal disease and hypertension.

Clin Sci (Lond) 2021 Sep;135(17):2165-2196

Department of Cellular and Integrative Physiology, University of Nebraska Medical Center, Omaha, NE 68198, U.S.A.

Hypertension is a major risk factor for cardiovascular disease, chronic kidney disease (CKD), and mortality. Troublingly, hypertension is highly prevalent in patients with autoimmune renal disease and hastens renal functional decline. Although progress has been made over the past two decades in understanding the inflammatory contributions to essential hypertension more broadly, the mechanisms active in autoimmune-mediated renal diseases remain grossly understudied. Read More

View Article and Full-Text PDF
September 2021

Efficacy and safety of belimumab in paediatric and adult patients with systemic lupus erythematosus: an across-study comparison.

RMD Open 2021 09;7(3)

IRCCS Istitutu Giannina Gaslini, Clinica Pediatrica e Reumatologia, PRINTO, Genova, Italy.

Objective: To assess the efficacy and safety of belimumab in paediatric versus adult patients with systemic lupus erythematosus (SLE).

Methods: We performed across-study comparisons of patients with active SLE who received belimumab or placebo, plus standard therapy, in PLUTO (paediatric phase II) and BLISS-52, BLISS-76, BLISS-NEA and EMBRACE (adult phase III). Analysed efficacy data included Week 52 SLE Responder Index (SRI)-4 response rate (EMBRACE: SRI with modified Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) proteinuria scoring (SRI-S2K)); SRI-4 response rate (EMBRACE: SRI-S2K) according to baseline disease activity indicators (Safety of Estrogens in Lupus Erythematosus National Assessment-Systemic Lupus Erythematosus Disease Activity Index (SELENA-SLEDAI) score; anti-dsDNA/C3/C4 levels); Week 52 SRI-6 response rate; and time to first severe flare (SELENA-SLEDAI Flare Index) over 52 weeks. Read More

View Article and Full-Text PDF
September 2021

Tocilizumab for massive refractory pleural effusion in an adolescent with systemic lupus erythematosus.

Pediatr Rheumatol Online J 2021 Sep 16;19(1):144. Epub 2021 Sep 16.

Division of Rheumatology, ERN RITA center, IRCCS Ospedale Pediatrico Bambino Gesù, Piazza Sant'Onofrio, 4-00165, Rome, Italy.

Background: Pleural effusion in systemic lupus erythematous (SLE) is a common symptom, and recent studies demonstrated that IL-6 has a pivotal role in its pathogenesis.

Case Presentation: We report a case of a 15 years old Caucasian boy with a history of persistent pleural effusion without lung involvement or fever. Microbiological and neoplastic aetiologies were previously excluded. Read More

View Article and Full-Text PDF
September 2021

The SLICC/ACR Damage Index (SDI) may predict adverse obstetric events in patients with systemic lupus erythematosus.

Lupus 2021 Sep 16:9612033211045061. Epub 2021 Sep 16.

Rheumatology, 199987Hospital Universitario Pedro Ernesto, Rio de Janeiro, Brazil.

Objective: The objective of this study was to evaluate the potential impact of irreversible damage accrual in women with systemic lupus erythematosus (SLE) and adverse maternal and/or fetal/neonatal outcomes.

Methods: Retrospective cohort study with SLE pregnant patients was carried out from January 2011 to January 2020 at the Hospital University Pedro Ernesto (HUPE) of the State University of Rio de Janeiro, Brazil. Irreversible damage was defined according to SLICC/ACR damage index (SDI). Read More

View Article and Full-Text PDF
September 2021

Antirheumatic Drug Intake Influence on Occurrence of COVID-19 Infection in Ambulatory Patients with Immune-Mediated Inflammatory Diseases: A Cohort Study.

Rheumatol Ther 2021 Sep 16. Epub 2021 Sep 16.

Adolphe de Rothschild Foundation Hospital, 29 Rue Manin, Paris, France.

Introduction: We aimed to study the prevalence of a history of COVID-19 infection among patients suffering from systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), Sjögren's syndrome (SjS) or psoriatic arthritis (PsA), and the potential influence of long-term hydroxychloroquine (HCQ) intake.

Methods: We performed an observational monocentric cohort study at the Adolphe de Rothschild Foundation Hospital ophthalmology division (Paris, France). Electronic medical records (EMR) data were searched for keywords associated with SLE, RA, SjS, or PsA. Read More

View Article and Full-Text PDF
September 2021

Systemic lupus erythematosus children in Egypt: Homeland spectrum amid the global situation.

Lupus 2021 Sep 16:9612033211043010. Epub 2021 Sep 16.

Pediatrics Department, Rheumatology and Nephrology Unit, 68789Alexandria University, Alexandria, Egypt.

Objectives: This study aims to present the manifestations of juvenile systemic lupus erythematosus (JSLE) across Egypt, to focus on age at onset and gender-driven influence on disease characteristics, and to compare findings to other countries.

Methods: The study included 404 Egyptian children with systemic lupus erythematosus (SLE) presenting to one of the specialized rheumatology centers corresponding to 13 major governorates. Juvenile cases age was ≤ 16°years at the time of recruitment. Read More

View Article and Full-Text PDF
September 2021

Relationship of Anifrolumab Pharmacokinetics With Efficacy and Safety in Patients With Systemic Lupus Erythematosus.

Rheumatology (Oxford) 2021 Sep 16. Epub 2021 Sep 16.

Centre for Inflammatory Disease Monash Health, Monash University, Melbourne, VIC, Australia.

Objectives: To characterize the relationship of anifrolumab pharmacokinetics with efficacy and safety in patients with moderate to severe SLE despite standard therapy, using pooled data from 2 phase 3 trials.

Methods: TULIP-1 and TULIP-2 were randomized, placebo-controlled, 52-week trials of intravenous anifrolumab (every 4 weeks for 48 weeks). For the exposure-response analysis, BILAG-based Composite Lupus Assessment (BICLA) or SLE Responder Index (SRI[4]) response rates at week 52 in each quartile/tertile of average anifrolumab serum concentration (Cave) were compared for anifrolumab and placebo in all-comers, patients who completed treatment, and interferon gene signature (IFNGS)-high patients who completed treatment, using average marginal effect logistic regression. Read More

View Article and Full-Text PDF
September 2021

Investigation of Genes Associated With Atherosclerosis in Patients With Systemic Lupus Erythematosus.

Arch Rheumatol 2021 Jun 27;36(2):287-295. Epub 2021 Jan 27.

Department of Medical Genetics, Trakya University, Faculty of Medicine, Edirne, Turkey.

Objectives: In this study, we aimed to identify patients with systemic lupus erythematosus (SLE) who are genetically at risk for developing atherosclerosis.

Patients And Methods: Between November 2014 and May 2016, a total of 38 patients with SLE (36 females, 2 males; mean age: 37.6 years; range, 18 to 71 years) and 32 healthy females (mean age: 31. Read More

View Article and Full-Text PDF

Risk of rheumatic disease in breast implant users: a qualitative systematic review.

Gland Surg 2021 Aug;10(8):2557-2576

Faculty of Medicine, Université de Montréal, Montreal, Quebec, Canada.

Background: Recent studies on the risk of rheumatic disease among breast implant users have reported conflicting results. The primary objective of this study was to provide a systematic and critical review of the literature on the association between breast implants and the risk of rheumatic disease.

Methods: A qualitative systematic review was conducted in PubMed, MEDLINE, EMBASE, EBM-Reviews and CINAHL Complete from database inception to June 23rd, 2021. Read More

View Article and Full-Text PDF